Drug news
Draft NICE guidance recommends Firmagon for Prostate Cancer-Ferring Pharma
NICE has issued new draft guidance recommending Firmagon (degarelix), from Ferring Pharmaceuticals, as an option for treating Prostate Cancer in people with spinal metastases who are at risk of impending spinal cord compression. The treatment has been approved for Prostate Cancer in the US and EU since 2008.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.